Esin Cengiz BODUROĞLU, Sultan Çiğdem IRKKAN, Tulu Ayata KEBAT

Meme karsinomlarında p53, c-erb B2 ve bcl-2 işaretleyicilerinin doku kesitinde ve ince iğne aspirasyon biyopsi materyallerinde karşılaştırmalı değerlendirilmesi

AMAÇ: Meme karsinomlarında ince iğne aspirasyon biyopsisi tanının ve bir kısım prognostik parametrenin belirlenmesi için cerrahi biyopsinin yerine uygun bir alternatif olarak kabul edilmektedir. Bu çalışmada ardışıkgönderilen 100 mastektomi spesmeninde tümörden ince iğne aspirasyon biyopsi yöntemi ile elde edilen örnekte p53, bcl-2, c-erb B2 immünboyamaları yapılmış ve doku boyamaları ile karşılaştırmalı olarak incelenmiştir. YÖNTEMLER: Doku fiksasyonu ve takibi aşamaları sonucu antijenitede gelişebilecek değişikliklerin önlenebilmesi için doku kesitleri frozen yöntemle çalışılmıştır. BULGULAR: Frozen kesitlerde yeterlilik %98.67, ince iğne aspirasyon biyopsisi materyallerinde yeterlilik %99.00 olarak bulunmuştur. Her üç antikorun doku ve ince iğne aspirasyon biyopsisi boyanmaları arasında istatistiksel anlamlı ilişki bulunmuştur (p

Anahtar Kelimeler:

meme kanseri, sitoloji; p53; c-erbB2; bcl-2

Matched comparison of p53, c-erb B2 and bcl-2 markers in breast cancer tissue and fine needle aspiration biopsy materials

OBJECTIVE: Fine needle aspiration biopsy in breast cancer is accepted to be an appropriate alternative to surgical biopsy both for diagnosis and to define some prognostic parameters. In this study comparison of p53, bcl-2, c-erb B2 immunoreactivities on both fine needle aspiration biopsy samples and tissue sections from 100 consecutive mastectomy specimen with breast cancer was performed.METHODS: Frozen samples of tissue were used in the study in order to eliminate the effects of the tissue processing. RESULTS: The adequacy of samples was 98.67% for the tissue sampling and 99.00% for the cytologic materials. There were statistically significant relationship between tissue and cytologic material for each of the three markers (p0.05). The sensitivity of p53 in cytologic material was quite low (50%) but sensitivity was high (92.3%). The sensitivity and the specifity for both bcl-2 and c-erb B2 were high (sensitivity 89.2%, 84.1% and specifity 92.5%, 89.6% respectively). CONCLUSION: Fine needle aspiration biopsy material could be used safely to determine p53, bcl-2, c-erb B2 in breast cancer, but it has to be kept in mind that the p53 specifity is quite low and p53 staining in cytologic material could lead to false negative results.

Keywords:

breast cancer, cytology; p53; c-erbB2; bcl-2,

PDF

___

Bell DA, Hajdu SI, Urban JA, Gaston JP. Role of aspiration management of mammary lesions in office practice. Cancer 1983;51:1182-9 diagnosis and
Rimm DL, Stastny JF, Rimm EB, et al. Comparison of fine-needle aspiration and open surgical biopsy as methods for obtaining a pathologic 1997;81:51-6 Cancer Cytopath
Rosenthal DL. Breast lesions diagnosed by fine needle aspiration. Pathol Res Pract 1986;181:645- 6
Gupta RJ, Dowle CS, Simpson JS. The value of needle aspiration cytology of the breast, with an emphasis on the diagnosis of breast disease in young women below the age of 30. Acta Cytologica 1990;34:165-8
Norton LW, Davis JR, Wiens JL, et al. Accuracy of aspiration cytology in detecting breast cancer. Surgery 1984;96:806-14
Mitteldorf CA, Alves VA, Kanamura CT, Carneiro PC. Immunocytochemistry applied to aspiration biopsy cytology. Acta Cytologica 1999;43:218-26
Bozzetti C, Nizzoli R, Naldi N, et al. Bcl-2 expression on fine-needle aspirates from primary breast carcinoma: correlation with other biologic factors. Cancer 1999;87:224-30
Fritzsche FR, Bode PK, Moch H, Kristiansen G, Varga Z, Bode B. Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization 2010;34:1180-5 Am J Surg Pathol
Hemachandran M, Nijhawan R, Joshi K. Cytological grading, apoptosis, and Bcl-2 protein expression in breast cancer. Diagn Cytopathol 2002;26:356-9
Park K, Han S. Cytologic Evaluation of p53, Cyclin D1, and Cathepsin D and Their Correlation with Histologic Sections in Primary Breast Carcinoma. J Korean Breast Cancer Soc 2002;5:113-7
Slooten HJ, Clahsen PC, Dierendonck JH, et al. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer 1996;74:78-85
Layfield LJ, Mooney EE, Glasgow B, et al. What constitute an adequate smear in fine-needle aspiration cytology of the breast? Cancer Cytopathol 1997;81:16-21
Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer 1993;72:3641-7
O’Malley FP, Saad Z, Kerkvliet N, et al. The predictive immunohistochemical assessment of p53 and c- erbB-2 in lymph node-negative breast cancer. Hum Pathol 1996;27:955-63 of semiquantitative
Poller DN, Hutchings CE, Galea M, et al. p53 protein expression in human breast cancer: Relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression and oestrogen receptor. Br J Cancer 1992;66:583-8
Davidoff AM, Herndon II JE, Glover N,et al. Relation established prognostic factors in breast cancer. Surgery 1991;110:259-64 overexpression and
Kline TS. Adequacy and aspirates from the breast: a philosophical approach. Diagn Cytopathol 1995;13:470-2
Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-6
Poller DN, Hutchings CE, Galea M, et al. p53 protein expression in human breast cancer: Relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression and oestrogen receptor. Br J Cancer 1992;66:583-8
Fisher CJ, Gillett CE, Vojtesek B, et al. Problems with p53 immunohistological staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer 1994;69:26-31
Horne GM, Anderson JJ, Tiniakos DG, et al. P53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer 1996;73:29-35
Elledge RM, Allred DC. The p53 tumor supressor gene in breast cancer. Breast Cancer Research and Treatment 1994;32:39-47
Ioakim-Liossi A, Markopoulos C, Karakitsos P, et al. p53 protein expression in benign and malignant breast lesions. Acta Cytol 1998;42:918-22
Hori M, Nogami T, Itabashi M, et al. Expression of bcl-2 in human breast cancer: Correlation between accumulation and DNA strand breaks associated with 1997;47:757-76 status, protein apoptosis. Pathology International
Zhang GJ , Kimijima I , Abe R , et al. Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogesis and progression of breast carcinomas. Clin Cancer Res 1997;3:2329-35
Zhang G, Kimijima İ, Tsuchiya A, Abe R. The role of bcl-2 expression in breast carcinomas. Oncology Reports 1998;5:1211-6
Troncone G, Zeppa P, Vetrani A, et al. Bcl-2 protein in breast cancer cells obtained by fine needle 1995;6:219-25 (FNA). Cytopathology
Albanell J, Bellmunt J, Molina R, et al. Node- negative breast cancers with p53 (-) /HER2-neu (-) status may identify women with very good prognosis. Anticancer Res 1996;16:1027-32
Toikkanen S, Helin H, Isola J et al. Prognostic significance of HER2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 1992;10:1044-8
Slamon D.J., Godolphin W, Jones LA, et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707- 712
Troncone G, Panico L, Vetrani A, et al. c-erbB-2 expression in FNAB smears and matched surgical specimens of breast cancer. Diagn Cytopatho 1996;14:135-9
Rimm DL, Stastny JF, Rimm EB, et al. Comparison of fine-needle aspiration and open surgical biopsy as methods for obtaining a pathologic 1997;81:51-6 Cancer Cytopath
Palombini L, Fulciniti F, Vetrani A, et al. Fine- needle aspiration biopsies of breast masses. Cancer 1988;61:2273-7